In a double‑blind randomized phase 2 trial for moderate-to-severe depression, both psilocybin therapy and escitalopram produced similar personality changes consistent with improved mental health (notably reduced neuroticism, disagreeableness and impulsivity, and increased openness), with only a possible selective increase in absorption after psilocybin. Changes following escitalopram were moderated by pre-trial positive expectancy, whereas expectancy did not moderate responses to psilocybin.
- Published
- Journal
- Psychological Medicine
- Authors
- Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., Erritzoe, D.